ASPPH logo


Member Research & Reports

Member Research & Reports

Harvard: Significant Barriers to Care for Patients Seeking Medication for Opioid Use

Buprenorphine-naloxone (buprenorphine), a highly effective, evidence-based treatment for opioid use disorder (OUD), is difficult to access in states with high rates of death associated with OUD, according to new research led by Harvard T.H. Chan School of Public Health. The study also found that access to buprenorphine is especially challenging among patients with Medicaid coverage.

“We were surprised to find roadblocks at every step of the process of getting buprenorphine, from finding a clinic with any prescribed, to finding one that will take public insurance,” said Dr. Michael Barnett, assistant professor of health policy and management at Harvard Chan School.

Read more.

Tags: ,